Currently Enrolling

    1. Interested in participating in our clinical trials, please complete this Contact Form


    2. OBOE STUDY – NOW ENROLLING PRIMARY PROGRESSIVE COHORT

    3. Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants with Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)(Sponsor: Genentech)

    This is an open-label, multicenter, biomarker study designed to be hypothesis-generating in order to better understand the mechanism of action of ocrelizumab and B-cell biology in patients with Relapsing MS or Primary Progressive MS.

    For more information, please contact Judy O’Connor/Jessica Siuta at 518-785-1000 (or)
    Research Line at 518-703-0695
    Click here for more information from ClinicalTrials website


  1. CHORDS STUDY

  2. An Open-Label Study To Evaluate the Effectiveness And Safety of Ocrelizumab In Patients with Relapsing Remitting Multiple Sclerosis Who Have Had A Suboptimal Response To An Adequate Course Of Disease-Modifying Treatment
  3. (Sponsor: Genentech)

This study will evaluate the efficacy and safety of ocrelizumab in participants with RRMS who have had a suboptimal response to an adequate course of DMT.

For more information, please contact Judy O’Connor at 518-785-1000.
Click here for more information from ClinicalTrials website


  1. ASCLEPIOS II

  2. A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis
    (Sponsor: Novartis)

The purpose of this study is to compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis

  1. For more information, please contact Judy B at 518-785-1000.
  2. Click here for more information from ClinicalTrials.gov

    A Prospective 24-Month Observational Study to Evaluate Neurocognitive Function and Safety in Patients with Relapsing Multiple Sclerosis Who Are Initiating LEMTRADA® Treatment in Routine Clinical Practice (Sponsor: Genzyme)

    More details to follow when information becomes available.


  3. Teriflunomide Male Transmission Study (Sponsor: Griffin Hospital)

    Assay of Teriflunomide Concentrations in Males Taking Teriflunomide for Treatment of Multiple Sclerosis and Their Female Sexual Partners

    To find out more about this study, please call Amy/Judy at 518-785-1000.
    Click here for more information on ClinicalTrials.gov: